In the 1p/19q non-codeletion status, the high expression of SESN2 was markedly relevant to a poorer prognosis of glioma (Figure 3A), while in the 1p/19q codeletion status, they had a relatively small correlation (Figure 3B). The gene discussed is SESN2; the disease is central nervous system cancer.